Cancer Trials

  • CANCER: Genomic Profiling IMPACT (MSK 12-245)

    The purpose of this genomic profiling study is to determine whether certain genes in cancer may be abnormal.

  • CANCER: Bladder/Urothelial Cancer A031701 (GU)

    This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

  • CANCER: Thoracic Cancer LUNGMAP

    This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400).

  • CANCER: Endometrial Cancer MSK 20-067

    This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.

  • CANCER: Ovarian Cancer NRG-CC008

    This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations.

  • CANCER: Bladder Cancer MSK 19-374

    This study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC). The researchers will test increasing doses of gemcitabine to find the highest dose that causes few or mild side effects when combined with BCG.

  • CANCER: Thoracic Cancer S1900E

    This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.

  • CANCER: Biospecimen s15-­01162

    This is a non-­interventional multicenter human research study in which we hope to better understand genetic and epigenetic changes that take place in T cells in Cutaneous T-­cell lymphoma (CTCL).

  • CANCER: Multiple Tumor Types TAPUR

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

  • CANCER: Breast Cancer A011801

    This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer.

  • CANCER: Thoracic Cancer MSK 20-415

    The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung cancer (NSCLC) than SBRT alone.

  • CANCER: Multiple Myeloma EAA181 (EQUATE)

    Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

  • CANCER: Prostate Cancer GU009 (PREDICT-RT)

    Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) *Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation

  • CANCER: Rectal Cancer MSK 19-288

    The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.

  • CANCER: Cervical Cancer GOG-3043

    This is a randomized controlled trial to compare survival for patients who underwent robotic assisted laparoscopy versus open radical hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.

  • CANCER: Breast Cancer MSK 21-183

    The purpose of this study is to find out how often the researchers can avoid an ALND in women with early-stage, node-positive HR+/HER2- breast cancer who are having upfront surgery. The study researchers think that, if AUS before surgery can help identify people who may have only 1 or 2 affected lymph nodes, it will be possible to perform the less radical standard SLNB during surgery.

  • CANCER: Leukemia SY-1425-202

    This is an open-label Phase 2 study in adult RARA-positive, previously untreated AML patients who are ineligible for standard induction therapy will consist of 3 parts.

  • CANCER: Lung Cancer - EA5182

    The primary objective of this trial is to evaluate progression-free survival (PFS) of osimertinib (AZD9291) and bevacizumab versus osimertinib (AZD9291) alone as first-line treatment for patients with metastatic EGFR-mutant lung cancers.

  • CANCER: Endometrial Cancer (GYN POEM Trial)

    The purpose of this study is to learn how cancer-related distress and/or reproductive concerns affect a woman's decision to remove or preserve her ovaries during surgery for endometrial cancer.

  • CANCER: Breast Cancer (CAMBRIA-1)

    We are doing this study to learn more about an experimental drug called camizestrant. We want to see if extended therapy with camizestrant is better at preventing disease recurrence (disease that comes back) than continuation of standard endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen, the drugs that you and other patients with early ER+/HER2- breast cancer are currently receiving). We also want to better understand the studied disease and associated health problems.

  • CANCER: Lung Cancer - Pragmatica

    This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent).

  • CANCER: Rectal Cancer - Janus

    This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer.

  • CANCER: Lung Cancer - Modulation of Lung Immune Responses to Viral Infection

    The purpose of this study is to examine interactions between lung immune cells and environmental microbial factors to understand immunological mechanisms.

  • CANCER: Assessing Barriers to Minorities' Participation in Oncology Clinical Trials

    The aim of this study is to assess baseline health literacy, healthcare information sources, clinical trial knowledge, as well as barriers to these, in Spanish-speaking Hispanics and other minorities served by Hartford HealthCare.

  • CANCER: Gastroesophageal Cancer - mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab

    The study's purpose is to determine if overall survival is improved in patients who received mFOLFIRINOX +/- nivolumab in comparison to FOLFOX +/- nivolumab as first-line chemotherapy for metastatic gastroesophageal adenocarcinoma.

  • CANCER: Genitourinary Cancer - GUIDANCE

    This study's aim is to identify whether or not intensifying or de-intensifying treatment for prostate cancer depending on genomic risk category will promote better health outcomes.

  • CANCER: Biospecimens (MSK 06-107)

    This protocol allows MSK to collect and keep biospecimen samples in order to conduct research in the present and maintained for future research.

  • CANCER: Pancreatic Cancer - Perioperative versus Adjuvant Chemotherapy

    This study seeks to determine whether giving chemotherapy both before and after surgery provides better patient outcomes compared to only giving chemotherapy after surgery in patients with pancreatic cancer.

  • CANCER: Lung Cancer - Early Detection of Tobacco-Associated Lung Cancer

    Lung cancer is the only tobacco-related malignancy that currently has an effective, widely recommended screening test: low dose CT (LDCT) of the chest. The purpose of this study is to evaluate how a combination of biomarkers acquired from various body fluids can perform compared to the current standard chest LDCT screening test.

  • CANCER: Hospice - Home Hospice Experience with Telemedicine

    Integration of the oncologist in the development of the patient's end-of-life care plan and medical decision-making process ("shared care") during the transition to hospice may remove known barriers to end-of-life care and impact the patient, family and care team's experience. This study serves to assess the feasibility of implementing this shared care model in a single-center, community-based hospital system, and measure the impact of the use of telemedicine to integrate the oncologist in the hospice setting.

  • CANCER: Breast Cancer - Trial to Minimize Non-Response to Aerobic Training

    This study is designed to evaluate the cardiorespiratory fitness (CRF) response rate to different aerobic therapy (AT) doses in patients with post-treatment primary breast cancer.

  • CANCER: Post Hospital Discharge

    This study seeks to assess the feasibility of a digital remote patient monitoring program with the aim of enhancing a patient's access to timely symptom management. This can lead to benefits in patient engagement, quality of life, and hospital utilization.

  • CANCER: Cancer-Based Anxiety - Anxiety Intervention for Latino/Latina/Hispanic Older Adults and Caregivers

    The Managing Anxiety from Cancer (MAC) intervention exists to help older adults with cancer and their caregivers, and is considered part of the standard of care. The MAC intervention, though, has not been culturally tailored to the latino/a or hispanic population, which in some cases experience clinically significant untreated anxiety. This study is designed to help tailor MAC for this population.

  • CANCER: Colorectal Cancer - Microbiota Modulation of Chemotherapy-related Pain and Fatigue

    This research project was designed to better understand the persistent pain and fatigue after cancer treatment. Using a bio-omics approach, the study will be the first to longitudinally investigate the relationship among lifestyle factors and gut/plasma microbiome pattern, and to explore the dynamic changes of microbial genomes to predict pain and fatigue in CRC patients.

  • CANCER: Colorectal Cancer - Colorectal Cancer Screening Cohort Study

    This is a two part study that examines various factors that influence colorectal screening behavior, and uses a multi-arm randomized trial to test a brief text messaging intervention designed to increase individuals' likelihood of engaging in colorectal cancer screening.

  • CANCER: Gynecological Cancer - Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

    The primary objective is to examine if letrozole monotherapy/maintenance is non-inferior to IV paclitaxel/carboplatin and maintenance letrozole with respect to PFS in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction.

  • CANCER: Liver Cancer - Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

    The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).

  • CANCER: Breast Cancer NRG-BR009

    This study seeks to determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

  • CANCER: Lung Cancer - MSK 21-465

    This study is to see whether or not intervention before progression in certain patients can produce better outcomes for these patients.

  • CANCER: Lung Cancer - KontRASt-06

    This is a non-randomized, open-label, single arm, multicenter, phase II study evaluating the antitumor activity and safety of JDQ443 single agent as first-line treatment for participants with locally advanced or metastatic KRAS G12C-mutated NSCLC. The study will have 2 non-comparative cohorts (Cohort A and B) that will recruit participants in parallel.

  • CANCER: Breast Cancer - A012103

    This study seeks to compare the effect of pembrolizumab versus observation in patients with early-stage triple-negative breast cancer who have achieved a pathologic complete response after preoperative chemotherapy + pembrolizumab.

  • CANCER: Melanoma - MSK 23-098

    The purpose of this trial is to see how well the vaccine IO102/IO103 works in people with inoperable melanoma. People in this study will get IO102/IO103 with two drugs: nivolumab and relatlimab. It is hoped that combining the vaccine with these anti-cancer medications will boost the immune system to fight cancer.

  • CANCER: Liver Cancer ML44719

    This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic hepatocellular carcinoma (HCC) who have Child-Pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety and efficacy of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.

Search This Section